An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies
NACompletedINTERVENTIONAL
Enrollment
600
Participants
Timeline
Start Date
Not specified
Conditions
HIV Infections
Interventions
DRUG
Zalcitabine
Trial Locations (1)
07110
Hoffmann - La Roche Inc, Nutley
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT00002118 - An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies | Biotech Hunter | Biotech Hunter